PDCD1 and neoplasm: Another research also focused on anti-PD-1 therapy in advanced melanoma, and they found that FMT and anti-PD-1 changed tumor microenvironment and gut microbiome which led to overcoming resistance of anti-PD-1 immunotherapy (87).